United Kingdom
# |
Name |
Debt to Equity Ratio |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
8.35
|
June 30, 2024 | USD 0.07 | -16.83% |
|
United Kingdom |
|
2 |
8.07
|
Aug. 31, 2023 | USD 0.13 | 4.36% |
|
United Kingdom |
|
3 |
0.53
|
June 30, 2024 | USD 23.61 | -1.99% |
|
United Kingdom |
|
4 |
0.48
|
Dec. 31, 2023 | USD 2.21 | 0.46% |
|
United Kingdom |
|
5 |
0.37
|
Dec. 31, 2023 | USD 0.24 | -0.40% |
|
United Kingdom |
|
6 |
0.36
|
Dec. 31, 2023 | USD 16.92 | 0.06% |
|
United Kingdom |
|
7 |
0.23
|
Dec. 31, 2023 | USD 0.05 | 1.59% |
|
United Kingdom |
|
8 |
0.23
|
Dec. 31, 2023 | USD 32.88 | 0.83% |
|
United Kingdom |
|
9 |
0.13
|
Dec. 31, 2023 | USD 1.16 | -5.69% |
|
United Kingdom |
|
10 |
0.12
|
Dec. 31, 2023 | USD 13.39 | 4.86% |
|
United Kingdom |
|
11 |
0.12
|
Dec. 31, 2023 | USD 3.01 | 2.73% |
|
United Kingdom |
|
12 |
0.08
|
March 31, 2024 | USD 11.13 | -2.11% |
|
United Kingdom |
|
13 |
0.05
|
March 31, 2024 | USD 0.80 | 0.38% |
|
United Kingdom |
|
14 |
0.04
|
March 31, 2024 | USD 1.69 | NA |
|
United Kingdom |
|
15 |
0.04
|
Dec. 31, 2023 | USD 0.70 | -3.05% |
|
United Kingdom |
|
16 |
0.02
|
Dec. 31, 2023 | USD 5.33 | 1.52% |
|
United Kingdom |
|
17 |
-4.39
|
Dec. 31, 2023 | USD 0.05 | -13.11% |
|
United Kingdom |
|
18 |
-21.25
|
Dec. 31, 2023 | USD 14.61 | -1.71% |
|
United Kingdom |
The Vaccines company in United Kingdom with the highest Debt to Equity Ratio is Allergy Therapeutics plc (LSE: AGY.L) at 8.35.
The Vaccines company in United Kingdom with the lowest Debt to Equity Ratio is 4basebio PLC (LSE: 4BB.L) at -21.25.
The top 10 Vaccines companies in United Kingdom by Debt to Equity Ratio are Allergy Therapeutics plc, Oncimmune Holdings plc, Genus plc, Autolus Therapeutics plc, hVIVO plc, Centessa Pharmaceuticals plc, GENinCode plc, Immunocore Holdings plc, Aptorum Group Limited and Bicycle Therapeutics plc.
The bottom 10 Vaccines companies in United Kingdom by Debt to Equity Ratio are 4basebio PLC, Proteome Sciences plc, Silence Therapeutics plc, Arecor Therapeutics plc, Virax Biolabs Group Limited, ECO Animal Health Group plc, Roivant Sciences Ltd., Mereo BioPharma Group plc, Bicycle Therapeutics plc and Aptorum Group Limited.